June 25, 2017
by inesp.alves
6 Comments
Therachon’s medicine in development for achondroplasia, TA-46, was granted Orphan Drug designation by the medicine agencies FDA and EMA. TA-46 is a type 3 fibroblast growth factor receptor antagonist addressing achondroplasia. This medicine is an inactive form of the receptor that … Continue reading
March 4, 2016
by inesp.alves
0 comments
One very important issue around clinical trials and many research projects (many are funded by public money) is that, at the end, the data and results are not published. In the site clinicaltrials.gov, when searching for studies in achondroplasia, it … Continue reading
May 26, 2014
by inesp.alves
2 Comments
The ECRAN/ECRIN meeting was very enlightening. I meet new people, from all over Europe, USA and Canada and heard their experience, knowledge and concerns about clinical trials. The presentations were pleasant, but others were quite disturbing, because many questions around … Continue reading